Publications
497 publications
- Date
- Relevance
-
Organisation chart 2025
This document gives an overview of the members of the Executive Board (RvB), the management of the National Health Care Institute ...
-
Multi-year research agenda
The multi-year research agenda of the National Health Care Institute provides direction on what we research. Our research ...
-
Report - Cost-effectiveness: recommendations for surrogate endpoints
The National Health Care Institute and similar government organisations in England, Canada, the United States, Colombia and ...
-
Taking care of good healthcare
-
Advice - continue reimbursing nirmatrelvir/ritonavir (Paxlovid®) for the treatment of COVID-19
Paxlovid® can be used for treating adults with a coronavirus infection (COVID-19) and a very high risk of severe progression of ...
-
Advice - reimburse lebrikizumab (Ebglyss®) for the treatment of moderate to severe eczema
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lebrikizumab ...
-
Advice - reimburse zilucoplan (Zilbrysq®) for the treatment of myasthenia gravis
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse zilucoplan ...
-
Advice - reimburse tebentafusp (Kimmtrak®) for the treatment of eye cancer
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse tebentafusp ...
-
Advice - expansion of the reimbursement conditions for inclisiran (Leqvio®) and bempedoic acid (Nilemdo®)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to amend the List 2 conditions for ...
-
Advice - reimburse olipudase alfa (Xenpozyme®) for the treatment of Niemann-Pick disease
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse olipudase alfa ...